Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapy. Issue 6 (2nd June 2016)

• Record Type: Journal Article
• Authors: Miura, Katsuhiro; Takahashi, Hiromichi; Nakagawa, Masaru; Izu, Asami; Sugitani, Masahiko; Kurita, Daisuke; Sakagami, Masashi; Ohtake, Shimon; Uchino, Yoshihito; Hojo, Atsuko; Kodaira, Hitomi; Yagi, Mai; Kobayashi, Yujin; Iriyama, Noriyoshi; Kobayashi, Sumiko; Kiso, Satomi; Hirabayashi, Yukio; Hatta, Yoshihiro; Takei, Masami
• Is Part Of: Leukemia & lymphoma. Volume 57:Issue 6(2016:Jun.)
• Page Start: 1335
• Page End: 1341
• Publication Date: 2016-06-02
• Subjects: Diffuse large B-cell lymphoma -- BCL2 -- MYC -- relapse -- refractory counts; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2015.1096352
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The clinical significance of concurrent expression of MYC and BCL2 protein, known as "double-expressor lymphoma" (DEL), among patients with relapsed or refractory aggressive B-cell lymphomas, remains unclear. A retrospective analysis was performed of 38 patients treated with a salvage treatment consisting of rituximab, ifosfamide, etoposide, cytarabine and dexamethasone followed by consolidative high-dose chemotherapies. A total of 17 cases (45%) were categorized as DEL using immunohistochemical assay with a cut-off value of positivity of 40% for MYC and 50% for BCL2, respectively. DEL was associated with a lower overall response rate (35% vs 71%, p = 0.0481), worse 2-year progression-free survival (9% vs 67%, p = 0.001) and overall survival (35% vs 71%, p = 0.037). This analysis suggests that DEL is common among patients with relapsed/refractory aggressive B-cell lymphomas and that such patients require novel treatment strategies.